Press Releases

Company News
Summary ToggleAcura Pharmaceuticals Advances LTX-04 and its LIMITx™ Technology
Jun 28, 2017

*** Peak blood levels of abused LIMITx doses can be reduced up to 65% ***

Read more

Summary ToggleAcura Pharmaceutical Initiates Second Clinical Study on LTX-04
May 18, 2017
PALATINE, Ill. , May 18, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company has completed enrollment and initiated dosing in a second Phase 1 human pharmacokinetic trial of

Read more

Summary ToggleAcura Pharmaceuticals Announces First Quarter 2017 Financial Results
May 12, 2017
PALATINE, Ill. , May 12, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the first quarter ended March 31, 2017 . The Company reported net income of $0.4 million for the

Read more

Summary ToggleAcura Pharmaceuticals Announces Fourth Quarter 2016 and Full Year 2016 Financial Results
Mar 31, 2017
PALATINE, Ill. , March 31, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the year and three months ended December 31, 2016 .

Read more

Summary ToggleAcura Pharmaceuticals and MainPointe Pharmaceuticals Announce Deal for Nexafed® Products
Mar 17, 2017

Expands Commercialization of Acura's Methamphetamine-Resistant Pseudoephedrine Products

Read more

Summary ToggleAcura Pharmaceuticals Common Stock To Trade On The OTCQB Market
Feb 15, 2017
PALATINE, Ill. , Feb. 15, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that shares of its common stock will begin to trade on the OTCQB® Market, which is operated by OTC Markets Group

Read more

Summary ToggleAcura Pharmaceuticals Exploring Strategic Alternatives
Jan 03, 2017

Roth Capital Engaged to Assist in the Process

Read more

Summary ToggleAcura Pharmaceutical Provides Development Update on its LIMITx(TM) Technology
Dec 14, 2016

FDA Provides Advice on Further Development of LTX-04

Read more

Summary ToggleAcura Pharmaceuticals Announces Third Quarter 2016 Financial Results
Nov 14, 2016
PALATINE, IL -- (Marketwired) -- 11/14/16 -- Acura Pharmaceuticals, Inc. ( NASDAQ : ACUR) , a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and nine months ended September 30, 2016 .

Read more

Summary ToggleAcura Pharmaceuticals to Host Third Quarter 2016 Financial Results Conference Call on November 15, 2016
Nov 09, 2016
PALATINE, IL -- (Marketwired) -- 11/09/16 -- Acura Pharmaceuticals, Inc. ( NASDAQ : ACUR) , a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company plans to report financial results for the third quarter 2016 following the close of financial markets on

Read more

Summary ToggleKemPharm Announces Licensing Agreement with Acura Pharmaceuticals for Aversion(R) Abuse-Deterrent Technology
Oct 18, 2016

Agreement focused on KemPharm's current and in-development IR Opioid Pipeline

Read more

Summary ToggleAcura Pharmaceuticals Announces Second Quarter 2016 Financial Results
Aug 08, 2016
PALATINE, IL -- (Marketwired) -- 08/08/16 -- Acura Pharmaceuticals, Inc. ( NASDAQ : ACUR) , a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and six months ended June 30, 2016 . The Company reported a net loss of $3.3 million for

Read more

Summary ToggleAcura Pharmaceuticals to Host Webcast on July 14, 2016 to Discuss Additional Data From Study AP-LTX-400
Jul 11, 2016

Data Supports Effectiveness of LIMITX(TM) Technology to Address Oral Opioid Abuse

Read more

Summary ToggleAcura Pharmaceutical's LIMITX(TM) Technology Successfully Confirms Oral Abuse Deterrence Capabilities
Jun 08, 2016

Topline Results From Study AP-LTX-400 Cohort 2

Read more

Summary ToggleAcura Pharmaceuticals Announces First Quarter 2016 Financial Results
May 02, 2016
PALATINE, IL -- (Marketwired) -- 05/02/16 -- Acura Pharmaceuticals, Inc. ( NASDAQ : ACUR) , a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the first quarter ended March 31, 2016 . The Company reported net loss of $3.4 million for the first

Read more

Summary ToggleIndiana Governor's Bill Signing Ceremony Recognizes the Role of Meth-Resistant Technology in Stemming State Meth Problem
Apr 28, 2016

Indiana-Based Acura Pharmaceuticals Commends Law Providing Pharmacists Additional Tools to Address Meth Production and Abuse

Read more

Summary ToggleAcura Pharmaceuticals Receives Second U.S. Patent for Novel Limitx(TM) Abuse Deterrent Technology
Apr 26, 2016

New Oral Opioid Abuse Technology

Read more

Summary ToggleAcura Pharmaceuticals to Host First Quarter 2016 Financial Results Conference Call on May 3, 2016
Apr 21, 2016
PALATINE, IL -- (Marketwired) -- 04/21/16 -- Acura Pharmaceuticals, Inc. ( NASDAQ : ACUR) , a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company plans to report financial results for the first quarter 2016 following the close of financial markets on

Read more

Displaying 19 - 36 of 143 results